Contribution
My Lords, I declare an interest as a former chair of the Human Fertilisation and Embryology Authority, where I witnessed the pain of those whose fertility was impaired. This question is not about the transgender identity of adults. Anyone who turns it into a debate about that is distracting from the issue. It is about very young children being deemed capable of assenting to medical interventions whose effects and risks they cannot understand.
Across UK law, the age at which a young person is deemed capable of consenting to significant activities is far from uniform. At 16, one may consent to sexual activity, leave home, work and join the Armed Forces, with parental permission. We just listened to a very solid debate about the harm that could be caused to young children under that age by social media. At 17, one may drive. At 18, one may serve on a jury, vote—at the moment—buy alcohol and enter contracts. This reflects the law’s recognition that maturity develops unevenly, but it also exposes a striking inconsistency.
We prohibit young people making irreversible decisions in almost every other domain until adulthood, while in the PATHWAYS trial of puberty blockers we will permit exceptionally young children to assent to powerful drugs whose effects they cannot grasp. How do the Government reconcile the exceptionally young ages for this trial? Parliament frequently makes decisions about medical limits—screening, assisted dying, affordability of new drugs, abortion regulation and so on—so it is no answer to say to leave it to the clinicians.
I suggest that a child does not have the legal competence to give effective consent to life-changing medical interventions. The evidence base shows how great the risks are to an individual child, who should not be used as a test case for future general medical advances. Views on this trial have fluctuated and it is reported that certain people opposed to it were removed from involvement. Following consultation this year, NHS England confirmed that MAF hormones will no longer be routinely commissioned or prescribed for under-18s. This aligns with the indefinite 2024 ban on puberty blockers, which will be reviewed in 2027. I urge the Government not to reduce age limits. Even 16 is safer than younger ages because more physical development has occurred. The PATHWAYS trial is an outlier; it allows enrolment of children as young as 11 and 12.
The central issue is consent. We have something in law called Gillick competence, which means that under-16s may consent if they demonstrate sufficient maturity and understanding. The Gillick case arose from a case about contraceptive advice, not irreversible medical interventions. The key question is: can a prepubescent child comprehend the long-term effects of puberty blockers or hormones? Does the Minister really believe that meaningful understanding is possible at that age?
The findings from the Cass review and others show risks: bone health deficits; fertility, pregnancy and offspring impacts; sexual function impairment; effects on brain maturation; and cardiovascular and haematological risks. The additional safeguards that were added to PATHWAYS acknowledge these risks; they do not remove the irreversibility.
We all have the greatest respect for the noble Baroness, Lady Cass, whose pioneering work raised the dangers of puberty blockers. It will be argued in this debate that there are special reasons for allowing the trial at such a young age, which she has put forward. One is to turn children away from illegally accessing these drugs, but it is very unlikely that this relatively small trial with selected children will lead them to believe that they can access these drugs legally. Possible harm reduction is not an aim of the trial and there will be no evidence that this is the outcome.
Another argument is the plight of distressed children living in stealth, but unless they stay at home and out of school, a child who presents as a member of the other gender or who has delayed puberty is likely to be highly visible at school, one way or the other, and still stressed. Moreover, there is no comparative trial, save a delay of 12 months. We will not find out whether children who are denied or given these drugs are in better shape in, say, five or 10 years’ time. Only retrospective data analysis can tell us that. A useful comparator would be holistic psychosocial support. Rather than a trial, there should be follow-ups on patients who have already taken these drugs, here and abroad, and a review of the regulation and the robustness of diagnosis.
May we be told how clinicians will test the child’s understanding of what may happen? How will they distinguish the parents’ understandable wish to relieve the child’s distress, which is a different concept from the child’s own assent? If this trial goes ahead—we do not know whether it has started—will the Government undertake never to permit another trial on any children aged under 18, or even 16? Will there be sufficient data collection, including on withdrawal and any ill effects? May we be assured that parents will not be punished or pressured into giving their consent?
Why can this trial not be replaced by the tracking of past use of puberty blockers? The Gender Recognition (Disclosure of Information) (England) Order came into force in March. It will allow the disclosure of formerly protected information and facilitate a retrospective observational study tracking the health outcomes of roughly 9,000 adults who were referred, as children, to the former Gender Identity Development Service at the Tavistock and Portman NHS Foundation Trust.
Fortunately, the NHS has now moved youth gender services away from medical intervention and towards holistic psychological and psychosocial support, in line with the Cass review. I hope the Minister will affirm that this is the future model and first resort for all young people presenting with gender dysphoria. There is also concern about overdiagnosis, given the sharp rise in recent years and the parallels with other mental health diagnostic trends. A study from the University of York showed that diagnoses of gender dysphoria had increased from one in 60,000 teenagers in 2011 to one in 1,200 10 years later—a rise too astonishing to be taken at face value.
My final question: bearing in mind the deluge of emails I have received from members of the public, what assessment have the Government made of the appropriate age at which a young person can understand and consent to puberty blockers and cross-sex hormones?